Hodgkin Lymphoma, Myeloma, Non Hodgkin Lymphoma
Conditions
Brief summary
This registry has been established to gain a better understanding of the clinical and biological characteristics and outcome of patients with lymphoid cancer
Detailed description
Lymphoid cancer including Hodgkin disease, non-Hodgkin lymphomas (NHL) and myeloma, represents the most common hematologic malignancy. Despite the overall prognosis improved in the last 10 years, there are many open issues that need to be addressed, specifically refractoriness to standard treatment, disease recurrence and outcome with new drug in the so called real world setting. Since the Hematology and Bone Marrow Transplant Unit at Ospedale Papa Giovanni XIII of Bergamo has developed specific tools to collect clinical data thought fully validated electronic charts and biological specimens thanks to a regulatory compliant biobanking program, the aim of this study is to collect clinical and biological information of lymphoid cancer patients. The cohort of patients enrolled will permit to analyze the practice pattern, perform biological correlative studies of great translational potential with relevance to clinical practice.
Interventions
OTHERPatient registry
Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
Sponsors
A.O. Ospedale Papa Giovanni XXIII
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female patients 18 years or older * Written informed consent * Confirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma
Exclusion criteria
\- Unconfirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 20 years | Analyzed for all patients as time from diagnosis to death as a result of any cause, stratified according to intervention and baseline characteristics |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free survival | 20 years | Analyzed only for patients in complete response, as time from achievement of the complete response to relapse or death due to disease or acute toxicity of treatment, stratified according to intervention and baseline characteristics |
| Progression-free survival | 20 years | Analyzed for all patients, as time from diagnosis to progression of disease or death as a result of any cause, stratified according to intervention and baseline characteristics |
| Biological correlative studies | 20 years | Association between clinical and biologic characteristics |
Countries
Italy
Contacts
Primary ContactAlessandro Rambaldi, MD
Backup ContactGiuseppe Gritti, MD, PhD
Outcome results
None listed